References
- Castaneto, M. S., D. A. Gorelick, N. A. Desrosiers, R. L. Hartman, S. Pirard, and M. A. Huestis. 2014. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence 144:12–41. doi:10.1016/j.drugalcdep.2014.08.005.
- Crum, R. M., J. C. Anthony, S. S. Bassett, and M. F. Folstein. 1993. Population-based norms for the mini-mental state examination by age and educational level. Journal of the American Medical Association 269:2386–94. doi:10.1001/jama.1993.03500180078038.
- Gurney, S. M. R., K. Scott, S. Kacinko, and B. C. Presley. 2014. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Science Review 26:53–78.
- Huffman, J. W., R. Mabon, M.-J. Wu, J. Lu, R. Hart, D. P. Hurst, P. H. Reggio, J. L. Wileyc, and B. R. Martinc. 2003. 3-indolyl-1-naphthylmethanes: New cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor. Bioorganic & Medical Chemistry 11:539–49. doi:10.1016/S0968-0896(02)00451-0.
- Kay, S. R., A. Flszbeln, and L. A. QpJer. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:261–76. doi:10.1093/schbul/13.2.261.
- Kokona, D., P. C. Georgiou, M. Kounenidakis, F. Kiagiadaki, and K. Thermos. 2016. Endogenous and synthetic cannabinoids as therapeutics in retinal disease. Neural Plasticity 2016:8373020. doi:10.1155/2016/8373020.
- Lerner, A. G., C. Goodman, O. Bor, and S. L. Ran. 2014. Synthetic cannabis substances (SPS) use and hallucinogen persisting perception disorder (HPPD): Two case reports. The Israel Journal of Psychiatry and Related Sciences 51:277–80.
- Litjensa, R. P. W., T. M. Brunt, G.-J. Alderliefstec, and R. H. S. Westerinka. 2014. Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. European Neuropsychopharmacology 24:1309–23. doi:10.1016/j.euroneuro.2014.05.008.
- Sheehan, D. V., Y. Lecrubier, H. K. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, B. Roxy, and G. C. Dunbar. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry 20:22–33.
- Tait, R. J., D. Caldicott, D. Mountain, S. L. Hill, and S. Lenton. 2016. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology (Phila) 54:1–13. doi:10.3109/15563650.2015.1110590.
- Zobor, D., T. Strasser, G. Zobor, F. Schober, A. Messias, O. Strauss, A. Batra, and E. Zrenner. 2015. Ophthalmological assessment of cannabis-induced persisting perception disorder: Is there a direct retinal effect? Documenta Ophthalmologica 130:121–30. doi:10.1007/s10633-015-9481-2.